Literature DB >> 23908406

The role of peritoneal dialysis in modern renal replacement therapy.

Catriona Goodlad1, Edwina Brown.   

Abstract

Most patients starting dialysis can choose between peritoneal dialysis and haemodialysis. There is little evidence proving that one form of dialysis is better than the other; although there may be an early advantage to peritoneal dialysis (PD) in young patients with residual function this effect is short-lived. Technique failure develops after years on PD so dialysis modality will often change during a long dialysis career. Quality of life studies, which must be interpreted carefully, indicate that patients require information about the impact of dialysis on their lifestyle as well as health-related outcomes so that they can choose the most suitable dialysis modality. Increasing numbers of frail elderly patients are starting dialysis; support in the home by nursing staff may facilitate the use of PD in this group. In the UK guidelines prioritise the patient's choice of dialysis modality (where feasible) based on good quality predialysis education. Cost of treatment is generally lower on PD, which is particularly recommended for patients with residual renal function and few comorbidities.

Entities:  

Mesh:

Year:  2013        PMID: 23908406     DOI: 10.1136/postgradmedj-2012-131406

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  9 in total

1.  Peritoneal dialysis catheter placement in the right lower quadrant is associated with a lower risk of catheter tip migration: a retrospective single-center study.

Authors:  Lei Lan; Jielong Jiang; Peng Wang; Wei Ren; Zhao Hu
Journal:  Int Urol Nephrol       Date:  2014-12-30       Impact factor: 2.370

2.  The financial impact of increasing home-based high dose haemodialysis and peritoneal dialysis.

Authors:  Frank Xiaoqing Liu; Catrin Treharne; Bruce Culleton; Lydia Crowe; Murat Arici
Journal:  BMC Nephrol       Date:  2014-10-02       Impact factor: 2.388

Review 3.  How to meet the demand for good quality renal dialysis as part of universal health coverage in resource-limited settings?

Authors:  Yot Teerawattananon; Alia Luz; Songyot Pilasant; Suteenoot Tangsathitkulchai; Sarocha Chootipongchaivat; Nattha Tritasavit; Inthira Yamabhai; Sripen Tantivess
Journal:  Health Res Policy Syst       Date:  2016-03-18

4.  Health policies on dialysis modality selection: a nationwide population cohort study.

Authors:  Yi-Chun Lin; Yen-Chung Lin; Chih-Chin Kao; Hsi-Hsien Chen; Chih-Cheng Hsu; Mai-Szu Wu
Journal:  BMJ Open       Date:  2017-01-11       Impact factor: 2.692

5.  Low-site versus traditional peritoneal dialysis catheterization: A meta-analysis.

Authors:  Lifeng Gong; Wei Xu; Weigang Tang; Jingkui Lu; Yani Li; Huaqin Jiang; Hui Li
Journal:  Medicine (Baltimore)       Date:  2020-11-25       Impact factor: 1.889

Review 6.  A Global Overview of the Impact of Peritoneal Dialysis First or Favored Policies: An Opinion.

Authors:  Frank Xiaoqing Liu; Xin Gao; Gary Inglese; Piyatida Chuengsaman; Roberto Pecoits-Filho; Alex Yu
Journal:  Perit Dial Int       Date:  2014-07-31       Impact factor: 1.756

7.  Peritoneal dialysis and in-centre haemodialysis: a cost-utility analysis from a UK payer perspective.

Authors:  Catrin Treharne; Frank Xiaoqing Liu; Murat Arici; Lydia Crowe; Usman Farooqui
Journal:  Appl Health Econ Health Policy       Date:  2014-08       Impact factor: 2.561

8.  Therapeutic Challenges to End-Stage Kidney Disease in a Patient with Tetralogy of Fallot.

Authors:  Ken Ohara; Tetsu Akimoto; Takuya Miki; Naoko Otani; Taro Sugase; Takahiro Masuda; Takuya Murakami; Toshimi Imai; Shin-Ichi Takeda; Yasuhiro Ando; Shigeaki Muto; Daisuke Nagata
Journal:  Clin Med Insights Case Rep       Date:  2015-11-15

9.  The Cost-Effectiveness of Kidney Replacement Therapy Modalities: A Systematic Review of Full Economic Evaluations.

Authors:  Fei Yang; Meixia Liao; Pusheng Wang; Zheng Yang; Yongguang Liu
Journal:  Appl Health Econ Health Policy       Date:  2020-10-13       Impact factor: 2.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.